




PHARMACEUTICAL 2019

Onconova Therapeutics Inc.
Rank 295 of 363





RealRate

PHARMACEUTICAL 2019

Onconova Therapeutics Inc. Rank 295 of 363



The relative strengths and weaknesses of Onconova Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Onconova Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Onconova Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is -74%, being 111% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	17,765
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,438
Liabilities, Non-Current	3,922
Other Assets	149
Other Compr. Net Income	-178
Other Expenses	-1,721
Other Liabilities	176
Other Net Income	1,151
Other Revenues	1,228
Property and Equipment	9.0
Research and Development	16,924
Selling, General and Administrative Expense	7,586

Output Variable	Value in 1000 USD
Assets	17,923
Liabilities	12,536
Expenses	22,789
Revenues	1,228
Stockholders Equity	5,387
Net Income	-20,410
Comprehensive Net Income	-20,499
Economic Capital Ratio	-74%